X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Pathways Laid Down By The CMS For Drug Price Negotiations

Content Team by Content Team
21st March 2023
in Drug Development, News
Pathways Laid Down By The CMS For Drug Price Negotiations

The Centers for Medicare & Medicaid Services issued preliminary instructions on March 15 on how it intends to negotiate medication pricing under Medicare, a power provided to the agency by 2022’s Inflation Reduction Act.

According to CMS officials, the clinical advantages and costs of therapeutic options would be the foundational starting point for the initial offers made in price negotiations for chosen top-selling, single-origin medications under Medicare. When selecting medications, the guidance groups combine indications and dosages of therapies with the same active ingredient, including biologics.

SVB Securities’ David Risinger stated in a client note that grouping drugs this way is crucial since it advances eligibility for discussion to the earliest approval across drug versions as well as prevents producers from utilizing a generic exception.

While Congress laid out comprehensive principles for Medicare to negotiate maximum reasonable medication prices, much of the procedure as well as the details were left to CMS to complete this year ahead of negotiations beginning in 2024 for a first set of ten medicines.

The initial set of pharmaceuticals will be announced no later than September 1 this year, as per the advice, implying that the list may be made public sooner than anticipated by an initial schedule. CMS has the authority to negotiate rates for up to 140 medications by 2033, beginning with self-administered Part D drugs in 2026 and 2027, followed by physician-administered Part B therapies in 2028.

Following CMS’s initial offer, drug producers might make a counteroffer and meet with CMS up to three times. The guidance outlines the elements CMS would consider when determining a drug’s value. CMS officials stated that the agency will initially assess the clinical advantages and net price of alternatives, followed by considerations such as research costs, patent protections, revenue, as well as federal support.

Drugmakers have already gone on to warn that the IRA might reduce investment in small-molecule medicines, which are exempt from the negotiation for seven years post-approval, vis-à-vis 11 years for biological, or large-molecule drugs. The law provides a negotiation timeframe that would make discounted prices effective two years after the medicine is chosen, resulting in the often-mentioned nine- and thirteen-year timelines.

CMS guidance would enable price discussions based on the first entry of an active therapeutic ingredient into the market, regardless of subsequent dosages or formulations, which would be initiated at a later stage.

The guidance reports that this technique of negotiating a single price across all dose forms and strengths is consistent with the regulatory need to negotiate a maximum fair price in the case of a selected drug. CMS believes that this will also allow for a more direct comparison with treatment alternatives, which may have different dosage forms, strengths, as well as frequency of use than the chosen drug.

CMS is seeking public feedback on its recommendations and will amend the document in response this summer. According to a CMS official, the agency has put in place an open-door policy for input, having monthly technical calls with drug manufacturers as well as roundtables with associations and healthcare offerors, and anybody who has a point to make, an experience to share, or information that may be brought to the agency’s attention.

The advisory was issued on the same day that Medicare announced 27 medicines whose makers would face penalties for raising their drug costs faster than the inflation rate.

Previous Post

MHRA In The UK To Assess Stem Cell Robots For Cell Therapies

Next Post

EMA Keeping A Close Watch On Critical Medicine Shortages

Related Posts

Clinical Development
Articles

AI Revolutionizing Drug Discovery and Clinical Development

19th April 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Drug-Development
Articles

China’s Super Me-Too Drug Development: A New Pharma Frontier

18th April 2025
Omics Based Clinical Trials
Asia

Asia Pacific Omics-Based Clinical Trials Market Growth

16th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Insights

AstraZeneca Eyes Acquisition To Develop Cell Therapies

24th March 2025
Next Post
U.S. FDA Approves DARZALEX Split-Dosing Regimen

EMA Keeping A Close Watch On Critical Medicine Shortages

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In